364 related articles for article (PubMed ID: 15766857)
1. Voice handicap index results for older patients with adductor spasmodic dysphonia.
Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
[TBL] [Abstract][Full Text] [Related]
2. Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia.
Anari S; Carding PN; Hawthorne MR; Deakin J; Drinnan MJ
Laryngoscope; 2007 Oct; 117(10):1888-92. PubMed ID: 17690610
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
4. Speech intelligibility in severe adductor spasmodic dysphonia.
Bender BK; Cannito MP; Murry T; Woodson GE
J Speech Lang Hear Res; 2004 Feb; 47(1):21-32. PubMed ID: 15072525
[TBL] [Abstract][Full Text] [Related]
5. Perceptual analyses of spasmodic dysphonia before and after treatment.
Cannito MP; Woodson GE; Murry T; Bender B
Arch Otolaryngol Head Neck Surg; 2004 Dec; 130(12):1393-9. PubMed ID: 15611398
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.
Rubin AD; Wodchis WP; Spak C; Kileny PR; Hogikyan ND
Arch Otolaryngol Head Neck Surg; 2004 Apr; 130(4):415-20. PubMed ID: 15096423
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
8. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of essential voice tremor: a study of 34 cases.
Sulica L; Louis ED
Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728
[TBL] [Abstract][Full Text] [Related]
10. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
11. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Adams SG; Hunt EJ; Charles DA; Lang AE
J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
13. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
[TBL] [Abstract][Full Text] [Related]
14. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
16. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia.
Roy N; Mauszycki SC; Merrill RM; Gouse M; Smith ME
Folia Phoniatr Logop; 2007; 59(2):83-90. PubMed ID: 17337898
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
Casserly P; Timon C
J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
[TBL] [Abstract][Full Text] [Related]
18. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection.
Sapienza CM; Cannito MP; Murry T; Branski R; Woodson G
J Speech Lang Hear Res; 2002 Oct; 45(5):830-43. PubMed ID: 12381042
[TBL] [Abstract][Full Text] [Related]
19. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
Courey MS; Garrett CG; Billante CR; Stone RE; Portell MD; Smith TL; Netterville JL
Ann Otol Rhinol Laryngol; 2000 Sep; 109(9):819-22. PubMed ID: 11007083
[TBL] [Abstract][Full Text] [Related]
20. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
